Retinal andVitreoretinal Diseases and Surgery
694
Surgical management |
|
610 |
Antibiotics during |
|
610 |
Strategies in the |
|
622 |
Trauma & |
614,618 |
Treatment of |
|
614 |
Antibiotics in the |
|
616 |
Vitrectomy as |
614,622 |
Epiretinal membranes |
|
571 |
Clinical findings |
|
574 |
Definition |
|
571 |
Diagnosis |
|
576 |
B-scan & |
|
576 |
OCT & |
|
577 |
Epidemiology |
|
572 |
Introduction |
|
571 |
Natural history |
|
573 |
Pathophysiology |
|
572 |
PVD & |
|
573 |
Treatment |
|
580 |
ERM peeling |
|
580 |
Vitrectomy |
|
580 |
Central core |
|
580 |
Dye stains |
|
582 |
Essential elements in surgery |
123,141 |
Advances in vitreoretina |
|
655 |
Evaluation of the central retina |
|
40 |
Fluorescein angiography |
|
11 |
Abnormal angiographic patterns |
|
18 |
Hyperfluorescence in |
|
19 |
Central serous |
|
21 |
chorioretinopathy |
Malignant melanoma |
|
20 |
Ocular histoplasmosis |
|
21 |
Retinal pigment epithelium |
|
19 |
detachment |
|
Hypofluorescence in |
|
19 |
Choroidal nevus |
|
21 |
Hemorrhagic detachment of |
|
21 |
RPE |
|
Vascular filling defects |
|
21 |
Age-related macular degeneration |
|
24 |
Anatomical features in |
|
11 |
Central serous chorioretinopathy |
|
24 |
Cystoid macular edema |
|
24 |
Diabetic retinopathy in |
|
22 |
Non-proliferative type |
|
22 |
Proliferative type |
22 |
How to use the |
12 |
Important factores in |
12 |
Indications of |
12 |
Interpretation of |
11 |
Normal angiographic pattern |
13 |
Choriocapillaris filling |
15 |
Choroidal perfusion |
16 |
Recirculation phase |
16 |
Sequence of events in |
14 |
Normal circulatory filling in |
12 |
Phases of |
13 |
Retinal vein occlusions in |
23 |
Retinoblastoma |
25 |
Side effects of |
13 |
Sodium fluorescein in |
12 |
The fluorescein dye in |
12 |
Gene therapy |
663 |
Corneal diseases |
673 |
Degenerative retinal disorders |
663,678 |
Function of the eye |
667 |
Glaucoma |
677 |
Inherited dystrophies |
664 |
Introduction |
664 |
Ocular cell tropism |
668 |
Optic neuropathies |
675 |
Promising prospects for therapies |
687 |
rAAV-Mediated ocular gene transfer |
665 |
Administration |
669 |
Efficiency |
670 |
Specificity |
666 |
Retinal disorders |
678 |
Transgene expression |
664 |
Giant retinal tears |
399 |
Additional tears |
402 |
Associated conditions |
400 |
Complications during surgery |
409 |
Definition |
400 |
Dyalisis vs |
400 |
Preoperative assessment |
400 |
Retinal flap |
402 |
Silicone oil controversy |
409 |
Subretinal proliferation |
409 |
Surgical principles |
402 |
Perfluorocarbon liquids use |
403 |
Indications for |
404 |
Retinal andVitreoretinal Diseases and Surgery
696
Treatment of macular area |
71 |
Types of |
69 |
Normal appearance of the retina |
10 |
Nutritional highlights |
629 |
Age-related Macular Degeneration & 629 |
Anti-oxidant enzymes |
636 |
Diabetic retinopathy |
639 |
Dietary supplements |
630 |
B carotene |
632 |
Copper |
637 |
Lutein |
633 |
Omega-3 fatty acids |
635 |
Vit. C |
630 |
Vit. E |
631 |
Zeaxanthin |
633 |
Zinc |
636 |
Introduction |
629 |
Risk factors |
638 |
Vascular diseases |
641 |
Observation of the fundus |
41 |
Drawing of the fundus |
47 |
Scleral depression |
48 |
Optical coherence tomography (OCT) |
27 |
Abnormal |
29 |
Age-related macular degeneration 29,36 |
Central serous chorioretinopathy |
30 |
Central venous occlussion |
31 |
Cystoid macular edema |
37 |
Diabetic retinopathy |
30,35 |
Epiretinal membranes |
34 |
Macular holes |
33 |
Retinal structures |
33 |
Anterior segment structures |
32 |
Application of |
32 |
Fluorescein angiography vs |
27 |
Fourier-domain |
36 |
Glaucoma in |
32 |
Evaluation of RNFL |
32 |
Imaging in |
32 |
Interpretation of |
28 |
Main considerations |
27 |
Normal |
29 |
Pathological macular disorders |
37 |
Refractive surgery application |
32 |
Resolution |
27 |
Ocular diagnosis systems |
39 |
Optical coherence tomography |
27,51 |
Wide angle fundus observation |
50 |
systems |
Pars plana lensectomy |
446,451 |
Complications |
456 |
Definition |
451 |
Indications for |
451 |
Luxated lens material |
454 |
Pediatric cases |
452 |
Removal of posterior capsule |
453 |
Surgical techniques |
452 |
Advances |
655 |
Aids during surgery |
455 |
Anterior vitrectomy |
454 |
Children |
454 |
Diabetics |
456 |
Penetrating trauma |
455 |
Primary posterior capsulorhexis |
454 |
Perfluorocarbon liquids |
141 |
Additional instrumentation |
147 |
Wide-field lenses |
148 |
Administration of |
149 |
Chemical properties |
141 |
Complications |
151 |
Avoiding |
151 |
Managing |
151 |
Dislocated lenses / IOL |
160 |
Lifting the IOL |
161 |
Vitrectomy during |
162 |
Fluorocarbon term |
142 |
Giant retinal tears |
153 |
Lensectomy |
153 |
Photocoagulation of |
155 |
Scleral buckling use |
153 |
Silicone oil use |
156 |
Slippage during surgery |
155 |
Small pupillary opening |
153 |
Unfolding the |
155 |
Handle of |
147 |
History |
141 |
Indications of |
143,152 |
Physical properties |
141 |
High specific gravity |
144 |
Interfacial tension |
145 |
Optical clarity |
145 |
Pressure |
146 |
Retinal andVitreoretinal Diseases and Surgery
698
Silicone |
377 |
Sponges |
377 |
Indirect ophthalmoscopy |
374 |
Initial steps |
370 |
Location of retinal breaks |
370,372 |
Marking retinal breaks |
372 |
Muscle isolation during surgery |
371 |
Operative field |
370 |
Sclera depression |
372 |
Sclerotomy |
379 |
Sealing the retina |
378 |
Diathermy vs cryotherapy |
378 |
Laser |
379 |
Sutures |
376 |
Placement techniques |
377 |
Visual results |
382 |
Proliferative vitreoretinopathy |
413,559 |
(PVR) |
Adjunctive medical treatment |
432 |
Antiproliferative agents |
432 |
Anti-VEGF |
433 |
Intravitreal steroids |
432 |
Anatomical considerations |
414 |
Background |
413 |
Causes |
414 |
Cell biology |
421 |
RPE cells |
421 |
Classification |
415 |
Clinical presentation |
417 |
Anterior cortex |
418 |
Epimacular membrane |
424 |
Location of membranes |
417 |
Proliferation |
417 |
Propagation of cells |
417 |
Star fold |
418 |
Subretinal fibrosis |
419 |
Clinical grades |
416 |
Clinical signs |
415 |
First |
425 |
Contraction types |
417 |
Location |
417 |
Definition |
414 |
Dynamics |
428 |
Features |
416 |
First signs |
425 |
Histology |
421 |
Risks factors |
|
414,426 |
Aphakia |
|
427 |
Choroidal detachment |
|
427 |
Large retinal tears |
|
427 |
Retinal detachment duration |
427 |
Trauma |
|
427 |
Vitreous hemorrhage |
|
427 |
Pathophysiological considerations |
|
422 |
Enrolled edges |
|
425 |
Inflammation |
|
422 |
Pigmented cells |
|
425 |
Proliferation |
423,425 |
PVR development |
|
423 |
Tobacco dust |
|
425 |
Uveo-vascular barrier |
|
423 |
Perspective |
|
433 |
PVR terminology |
|
415 |
Surgical treatment |
|
429 |
Anatomical outcomes |
|
429 |
Membrane peeling |
|
429 |
Release of fibrovascular traction |
|
429 |
Scleral buckle use |
|
429 |
Scleral depression |
|
429 |
Severe PVR |
|
430 |
Vitrectomy |
|
429 |
Retinal Laser treatments/Degenerations 111
Complications |
120 |
Indications for |
118 |
Intraocular currents |
112 |
Introduction to |
111 |
Peripheral retinal lesions |
113 |
Predisposing lesions |
114 |
Cystic retinal tuft |
114,115 |
Degenerative retinoschisis |
114,115 |
Dialysis |
114,118 |
Lattice degenerations |
114 |
Retinal tears |
114,117 |
Trophic retinal holes |
114,116 |
Physiological mechanisms |
111 |
Posterior vitreous detachment |
113 |
Retinopexy and |
119 |
Techniques of |
119,120 |
Parameters |
120 |
Vitreoretinal attachments |
113 |
Vitreous conditions during |
111 |
Vitreous liquefaction |
112 |
Retinal andVitreoretinal Diseases and Surgery
700
Toxicity |
534 |
The normal retina |
03 |
The optic nerve |
08 |
The vitreous |
09 |
Traction maculopathies |
345 |
Cause of traction |
345 |
Classification |
345 |
Cellophane maculopathy |
347,351 |
Surgical steps |
353 |
Vitrectomy |
353 |
Counseling |
349 |
Diagnostics |
347 |
Binocular ophthalmoscopy |
348 |
Electrophysiology |
349 |
Fluorescein angiography |
349 |
Optical coherence tomography |
348 |
Slit-lamp biomicroscopy |
347 |
Epimacular proliferation |
346,354 |
Maculorhexis in |
356 |
Removal of |
355 |
Radial peel |
356 |
Surgical steps of |
355 |
ILM removal techniques |
358 |
Instrumentation |
359 |
Introduction |
345 |
Macular hole |
347,357 |
Staining during surgery |
358 |
Surgical steps |
357 |
Macular pucker |
347,354 |
Pathogenesis |
345 |
Surgical management |
359 |
Apple-peel technique |
362 |
FILMS technique |
364 |
ILM removal techniques |
358 |
Keyhole technique |
359 |
Pinch technique |
360 |
Staining ILM |
362 |
Traction |
345 |
Treatment |
350 |
Vitreomacular traction syndrome |
347,350 |
Ultrasound B |
43 |
Indications of |
43 |
Vitreous components |
09 |
Wide angle fundus observation systems 50,63
BIOM |
56 |
Contact-lens type |
54 |
Field of view |
60 |
Indirect vs direct images |
55 |
Introduction |
53 |
Non-contact type |
56 |
OFFISS |
57 |
Plano-concave lenses |
53 |